HopeStage
Back to all studies
CompletedEUCTR 2005-004881-17

Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major d...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesBipolarity
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who was this study for?

This study was for people with bipolarity. Other eligibility criteria applied.

Listed locations
Austria · Denmark and 4 more locations
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
300
Sponsor
Institut de Recherches Internationales Servier [...] 1. Institut de Recherches Internationales Servier 2. Laboratorios Servier S.L. (For Spain only)
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Austria, Denmark, Finland, ...
Age range
Not clearly listed
Official registry ID
EUCTR 2005-004881-17
Official title
Show the full official title

Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major d...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Austria · Denmark · Finland

3 more locations
  • Germany
  • Netherlands
  • Spain
Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Institut de Recherches Internationales Servier [...] 1. Institut de Recherches Internationales Servier 2. Laboratorios Servier S.L. (For Spain only), a research institute.

Who was this study for?

This study was for people with bipolarity. Other eligibility criteria applied.

Want to explore more studies?

Explore studies